April 30, 2025
The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents […]
April 29, 2025
Today, the US Food and Drug Administration (FDA) approved prademagene zamikeracel cellular sheets (pz-cel, Zevaskyn), the first autologous cell-based gene therapy for treating wounds in adults […]
April 29, 2025
The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arthritis (GCA) in adults. This is […]
April 25, 2025
The US Food and Drug Administration (FDA) has approved penpulimab-kcqx (Akeso Biopharma) in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with […]
April 25, 2025
The National Institute for Health and Care Excellence (NICE) has recommended ribociclib (Kisqali, Novartis) as an adjuvant treatment for early breast cancer in patients at high […]
April 23, 2025
The National Institute for Health and Care Excellence (NICE) has recommended nivolumab (Opdivo) plus ipilimumab (Yervoy) for some people in England with advanced colorectal cancer. The […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who […]
April 18, 2025
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class prescription digital therapeutic for the preventive treatment of […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved a new indication for osilodrostat (Isturisa, Recordati) as second-line treatment of endogenous hypercortisolemia in adults with Cushing […]